The IC2 monoclonal autoantibody and its biotinylated, HRP, FITC and PE conjugated formats are planned to be commercial available from September 1st, 2011 after stability and quality control. Antibody-online.com will on commission contract with ImmunoSigns do both marketing and sale, but the products will also be directly available from ImmunoSigns in Copenhagen directly from this […]
The IC2 monoclonal autoantibody and its biotinylated, HRP, FITC and PE conjugated formats are planned to be commercial available from September 1st, 2011 after stability and quality control. Antibody-online.com will on commission contract with ImmunoSigns do both marketing and sale, but the products will also be directly available from ImmunoSigns in Copenhagen directly from this […]
A large scale production of the native IgM IC2 monoclonal autoantibody is under execution on contact with the Chech Rebublicbiotech company EXBIO.
Stanford University. Millegen Biotech and University of Copenhagen has collaborated supported by Juvenile Diabetes Research Foundation in the development of a new recombinant bioluminescent fusion protein scFv-Gluc, with the aim of testing the new format for in vivo noninvasive biolumeniscent imaging (BLI) of beta-cells in whole animals and pancreas tissue. The first fusion protein is […]
ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.
The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.